


REMARKS

A marked up version and a clean version of the substitute specification accompany this Amendment. The substitute specification reflects the inclusion of several sequence identifiers, as well as the correction of several sequence identifiers and a typographical error. By this Amendment, please also insert the accompanying sequence listing in the specification before the claims. Further, claims 1, 5, 6, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 and 29 have been amended to include the corresponding sequence identifiers. Claims 18-27 have also been amended to correct a typographical error by deleting a duplicative "the." No new matter has been added.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Melissa Handler, Ph.D.
Attorney for Applicant
Reg. No. 52,988
(609) 252-4323

Date: June 12, 2006